Nano-X Imaging Ltd.

What they do

Nano-X Imaging Ltd. was incorporated in Israel in 2018 and commenced operations in 2019. The company is engaged in research, development, manufacturing, and commercialization activities for its X-ray source technologies, the Nanox.ARC and Nanox.ARC X, and the Nanox.CLOUD, which together comprise the Nanox System. These products are intended for medical imaging applications. The company operates through a corporate structure that includes consolidated subsidiaries, and it generates limited revenue relative to its operating expenses.

Revenue drivers

• Nanox System commercialization — The company's primary revenue driver is the commercialization of the Nanox System, which includes the Nanox.ARC and Nanox.ARC X imaging devices and the Nanox.CLOUD platform. Revenue is generated from the sale or deployment of these systems. As of 2025, revenue was $13.0 million, up from $11.3 million in 2024.
• X-ray source technologies — Nano-X Imaging develops proprietary X-ray source technologies that are core to its imaging systems. Revenue related to these technologies may include component sales or licensing, though the company's filings indicate that commercialization is still in early stages.
• Geographic expansion — The company operates in multiple jurisdictions, including Israel and South Korea, and its revenue may be derived from various regions. However, specific geographic revenue breakdowns are not detailed in the provided excerpts.

Recent performance

For the fiscal year ended December 31, 2025, Nano-X Imaging reported revenue of $13.0 million, an increase from $11.3 million in 2024. The company incurred a net loss of $75.0 million in 2025, compared to a net loss of $53.5 million in 2024. Diluted earnings per share were negative $1.16 in 2025, versus negative $0.91 in 2024. Operating cash flow remained negative at $40.8 million for 2025, similar to the $36.6 million used in 2024. As of December 31, 2025, the company had total assets of $162.2 million, total liabilities of $22.4 million, and shareholders' equity of $139.7 million, with cash and cash equivalents of $49.2 million.

Strategy

Nano-X Imaging's stated strategy focuses on research, development, manufacturing, and commercialization of its X-ray source technologies and the Nanox System, which includes the Nanox.ARC, Nanox.ARC X, and Nanox.CLOUD. The company aims to demonstrate the feasibility of its technology for commercial applications. Management's priorities include advancing these activities and expanding commercialization efforts. The company has a history of recurring losses and negative operating cash flows, and it continues to invest in its product development and commercialization initiatives. No specific new strategies or partnerships are detailed in the provided excerpts beyond the ongoing focus on the Nanox System.

Risks

• History of losses and negative cash flows — Nano-X Imaging has incurred net losses and negative operating cash flows in each year from 2021 to 2025, including a net loss of $75.0 million and operating cash outflow of $40.8 million in 2025, which may continue.
• Commercialization and regulatory risk — The company's ability to successfully demonstrate the feasibility of its technology for commercial applications is uncertain, and its products may not achieve widespread adoption or regulatory approvals.
• Liquidity and capital needs — With cash and cash equivalents of $49.2 million as of December 31, 2025, and ongoing cash outflows, the company may need additional financing, which could be dilutive or difficult to obtain.
• Concentration in early-stage technology — Nano-X Imaging's business depends on the Nanox System, which is still in development and early commercialization stages, and failure to successfully commercialize could materially harm the company.

Outlook

The provided excerpts do not contain specific forward-looking guidance from management regarding future financial performance. However, the company's stated focus remains on advancing research and development, manufacturing, and commercialization of its Nanox System. Management acknowledges a history of recurring losses and the need to achieve commercial viability. No specific timelines or projections for profitability or product launches are included in the available excerpts.